FHIR © HL7.org  |  FHIRsmith 4.0.1  |  Server Home  |  XIG Home  |  XIG Stats  | 

FHIR IG analytics

Packageflute.requirements
Resource TypeRequirements
IdRequirements-F-PIL-2.json
FHIR VersionR5
Sourcehttps://build.fhir.org/ig/hl7-eu/flute-requirements/Requirements-F-PIL-2.html
URLhttps://flute.com/Requirements/F-PIL-2
Version0.1.0
Statusdraft
Date2023-10-25T10:31:30.239Z
NameF_PIL_2
TitleF-PIL-2
Authorityhl7
DescriptionCohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.
PurposeFLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners.
CopyrightHL7 Europe
Copyright LabelFederated Learning and mUlti-party computation Techniques for prostatE cancer

Resources that use this resource

No resources found


Resources that this resource uses

No resources found


Narrative

Note: links and images are rebased to the (stated) source

ID: F-PIL-2

Publisher: HL7 Europe

Contact Name Contact Points
HL7 Europe

Description:

Cohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.

Purpose:

FLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners.

Copyright Label: Federated Learning and mUlti-party computation Techniques for prostatE cancer


Statements:

ID: F-PIL-2

Label: Cohorts SHALL consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.

Sources:

  • HL7 Europe
Conformance Requirement
SHALL

consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE


Source1

{
  "resourceType": "Requirements",
  "id": "F-PIL-2",
  "text": {
    "status": "extensions",
    "div": "<!-- snip (see above) -->"
  },
  "url": "https://flute.com/Requirements/F-PIL-2",
  "version": "0.1.0",
  "name": "F_PIL_2",
  "title": "F-PIL-2",
  "status": "draft",
  "date": "2023-10-25T10:31:30.239Z",
  "publisher": "HL7 Europe",
  "contact": [
    {
      "name": "HL7 Europe",
      "telecom": [
        {
          "system": "url",
          "value": "https://www.hl7.eu"
        }
      ]
    }
  ],
  "description": "Cohorts shall consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.",
  "purpose": "FLUTE specific requirements for FLUTE pilot studies and the platform are outlined based on discussions with stakeholders participating in the case studies, in particular representatives of technical partners participating in WP5 (Quibim) and medical researchers from the three participating hospitals CHUL, IRST and VHIR, which also act as data owners.",
  "copyright": "HL7 Europe",
  "copyrightLabel": "Federated Learning and mUlti-party computation Techniques for prostatE cancer",
  "statement": [
    {
      "key": "F-PIL-2",
      "label": "Cohorts SHALL consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE.",
      "conformance": [
        "SHALL"
      ],
      "requirement": "consist of men with clinical suspicion of PCa based on a PSA > 3.0 ng/ml and/or abnormal DRE",
      "source": [
        {
          "display": "HL7 Europe"
        }
      ]
    }
  ]
}